Morphotek, Inc., a biopharmaceutical company and subsidiary of Eisai Corporation of North America, initiated Phase II of the study of its MORAb-009 monoclonal antibody to assess the capabilities of [...]" (2009-3-5)
jeudi 5 mars 2009
New Mesothelioma Clinical Trial Begins
"A study evaluating the effectiveness of an antibody to stop the growth of mesothelin, a protein excessively produced in tumors present in mesothelioma patients, began March 2.
Morphotek, Inc., a biopharmaceutical company and subsidiary of Eisai Corporation of North America, initiated Phase II of the study of its MORAb-009 monoclonal antibody to assess the capabilities of [...]" (2009-3-5)
Read more...
Morphotek, Inc., a biopharmaceutical company and subsidiary of Eisai Corporation of North America, initiated Phase II of the study of its MORAb-009 monoclonal antibody to assess the capabilities of [...]" (2009-3-5)
